Lutathera (lutetium Lu 177 dotatate) (Revised)

By August 26, 2026: Billing and prior authorization teams must update all systems and workflows to reflect this revised Lutathera policy across Medicare and Medicaid programs in FL, KY, SC, and VA. SPECIFIC ACTIONS: (1) Update prior authorization workflows to require and verify all three approval criteria before processing claims; (2) Implement dose modification logic in billing/claims systems to flag claims exceeding maximum 4 doses within 8-week intervals for review; (3) Modify encounter templates and clinical documentation requirements to capture somatostatin receptor imaging results and specific NET diagnosis details (gastroenteropancreatic, lung, thymus, pheochromocytoma/paraganglioma); (4) Train prior authorization staff on mandatory premedication requirements (long-acting octreotide timing: discontinue 4 weeks pre-treatment, administer 4-24 hours post-dose, continue up to 18 months post-treatment) and amino acid infusion protocols (L-lysine/L-arginine starting 30 minutes before Lutathera); (5) Create decision trees in PA system for dose modifications based on adverse reaction severity (first occurrence Grade 2-4 thrombocytopenia = hold until resolution; recurrent Grade 2-4 = permanent discontinuation); (6) Flag all claims for monitoring of long-term toxicity risks including MDS/leukemia and renal impairment. WHO: Prior authorization team, billing team, claims processors, and clinical reviewers. WHERE: Update in billing software, claims adjudication system, PA portal, and EMR templates. CONSEQUENCE: Claims submitted without proper prior authorization or missing required documentation (imaging confirmation, diagnosis specificity, prior therapy verification) will be denied. Off-label dosing or failure to implement dose modifications will result in claim denials and potential fraud/abuse issues.